Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	39.10B +320.8%
Revenue (ttm)	6.35B +2.8%
Net Income	903.25M +19.1%
EPS	1.66 +19.4%
Shares Out	543.49M
PE Ratio	43.29
Forward PE	42.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	886,000
Average Volume	1,505,396
Open	71.05
Previous Close	71.95
Day's Range	69.15 - 72.70
52-Week Range	20.15 - 92.00
Beta	0.55
RSI	67.37
Earnings Date	Nov 14, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,537
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY